Clinical Trial Search

Primary: Participants With Complete Remission (CR) at 24 Months — 3 Participants

Primary: Probability of Progression-free Survival (PFS) — 52 percentage probability

Primary: Number of Adverse Events as a Measure of Safety and Tolerability — 8; 40; 7; 41 participants

Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients

Primary: Number of Confirmed Responses (Complete or Partial Response Noted as the Objective Status for a Duration of at Least 2 Months) at 6 Months — 31 Participants

Primary: Change in Gene Expression Post Chemo — 30; 50 Percent change in cells

Primary: Overall Response Rate — 77.8 % of participants with response by PI

Primary: Progression-free Survival (PFS) — 16.5; 11.1 Months — p=<0.0001

Primary: Overall Response Rate (ORR) — 39 participants

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

Primary: Progression-free Survival (PFS) — 981.0; 1212.0 Days — p=<.0001

Primary: Number of Participants With Complete Response (CR) — 14 participants

Primary: Progression Free Survival (PFS) Based on Investigator Assessment — 106.9; 15.0 months — p=< 0.0001

Primary: PFS (Progression Free Survival) — NA; 18.9 Months — p=<0.0001

Primary: Complete Response — 45 Percentage of Participants

Primary: Overall Response Rate (ORR) — 25 Participants

Primary: Best Response — 20; 3; 3 Participants

Primary: Number of Participants With Complete Remission (CR) — 185 Participants

Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…

Primary: Progression-free Survival (PFS) — 31.1; 11.1 Months — p=<0.0001

Primary: Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart — 1 participants

Primary: Primary Analysis: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 30 — 78.5; 31.1…

Primary: Maximum Tolerated Dose (MTD) of Vorinostat That Can be Combined With Fludarabine Phosphate, Cyclophosphamide and Rituximab (FCR) (Phase I) — 400; 400 mg

Primary: Progression-free Survival (PFS) — 15.7; 28.9 months — p=<0.0001

Primary: MRD Cohort: 1-Year Disease-Free Survival (DFS) Rate in Confirmed uMRD Randomized Participants — 100.0; 95.3 percentage of participants — p=0.1475

Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants

Primary: Number of Subjects Maintaining Partial Response (PR) or Complete Response (CR) — 17 participants

Primary: Overall Responders (Complete and Partial Response) — 8; 18 participants

Primary: Overall Participant Response — 44; 1; 10 Participants

Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 6; 1 number of patients without DLT